Unknown

Dataset Information

0

DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon.


ABSTRACT: Mutations in the DMD gene are causative for Duchenne muscular dystrophy (DMD). Antisense oligonucleotide (AON) mediated exon skipping to restore disrupted dystrophin reading frame is a therapeutic approach that allows production of a shorter but functional protein. As DMD causing mutations can affect most of the 79 exons encoding dystrophin, a wide variety of AONs are needed to treat the patient population. Design of AONs is largely guided by trial-and-error, and it is yet unclear what defines the skippability of an exon. Here, we use a library of phosphorodiamidate morpholino oligomer (PMOs) AONs of similar physical properties to test the skippability of a large number of DMD exons. The DMD transcript is non-sequentially spliced, meaning that certain introns are retained longer in the transcript than downstream introns. We tested whether the relative intron retention time has a significant effect on AON efficiency, and found that targeting an out-of-frame exon flanked at its 5'-end by an intron that is retained in the transcript longer ('slow' intron) leads to overall higher exon skipping efficiency than when the 5'-end flanking intron is 'fast'. Regardless of splicing speed of flanking introns, we find that positioning an AON closer to the 5'-end of the target exon leads to higher exon skipping efficiency opposed to targeting an exons 3'-end. The data enclosed herein can be of use to guide future target selection and preferential AON binding sites for both DMD and other disease amenable by exon skipping therapies.

SUBMITTER: Goossens R 

PROVIDER: S-EPMC10481881 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

<i>DMD</i> antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon.

Goossens Remko R   Verwey Nisha N   Ariyurek Yavuz Y   Schnell Fred F   Aartsma-Rus Annemieke A  

RNA biology 20230101 1


Mutations in the <i>DMD</i> gene are causative for Duchenne muscular dystrophy (DMD). Antisense oligonucleotide (AON) mediated exon skipping to restore disrupted dystrophin reading frame is a therapeutic approach that allows production of a shorter but functional protein. As DMD causing mutations can affect most of the 79 exons encoding dystrophin, a wide variety of AONs are needed to treat the patient population. Design of AONs is largely guided by trial-and-error, and it is yet unclear what de  ...[more]

Similar Datasets

| S-EPMC4701541 | biostudies-literature
| S-EPMC6168132 | biostudies-literature
| S-EPMC5854547 | biostudies-literature
| S-EPMC8037683 | biostudies-literature
| S-EPMC1933433 | biostudies-literature
| S-EPMC4811139 | biostudies-literature
| S-EPMC8355726 | biostudies-literature
| S-EPMC7241300 | biostudies-literature
| S-EPMC6465270 | biostudies-literature
| S-EPMC1243800 | biostudies-literature